Encellin
PrivateLast Round
Series A
Dec 13, 2023
Est. Valuation
$2.14M
Total Funding Raised
$15.95M
Company Overview
Encellin operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Series A round in December 2023.
Encellin is a biotechnology company that develops an innovative thin-film cell encapsulation device for cell-based therapeutics to treat type 1 diabetes and other endocrine disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Encellin Comparables
Compare Encellin with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Seraxis | 86% | |
| Sernova Biotherapeutics Inc. | 83% | |
| Betalin Therapeutics | 82% |
For institutional investors. Book with your work email.
Encellin Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 13, 2023 | ||||
| Seed | Aug 5, 2021 | ||||
| Accelerator | Aug 20, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Encellin Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Khosla Ventures | Seed, Series A |
| Y Combinator | Seed, Series A, Accelerator |
| SV Latam Capital | Seed |
| Sand Hill Angels | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 13, 2023
$10M round led by Khosla Ventures
- Aug 5, 2021
$6M round led by Khosla Ventures and SV Latam Capital.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 22, 2026
Encellin is developing ENCRT to enable transplanted cells to survive and function while protected from the immune system, with a planned safety study in people with Type 1 diabetes to be conducted in Canada.
- partners_withSep 22, 2026
Encellin and BreakthroughT1D partnered on Sep 22nd '26 to advance the ENCRT-103-hPI clinical program for Type 1 Diabetes, including a planned trial in Canada.
For institutional investors. Book with your work email.
Encellin Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Encellin's valuation, stock price, and market status.
Is Encellin a public or private company?
Encellin is a private company.
What is the current stock price of Encellin?
Encellin is a private company, so its shares have no public market price. Caplight tracks Encellin's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Encellin worth (valuation)?
Encellin's valuation is estimated at $2.1M based on funding round data.
Can I buy Encellin stock?
Encellin shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Encellin's last funding round?
Encellin's most recent funding round was Series A on December 13, 2023.
Who are the main investors in Encellin?
Key investors in Encellin include Khosla Ventures, Y Combinator, SV Latam Capital.
Will Encellin IPO soon?
No public IPO plans have been announced for Encellin.
How can I track Encellin secondary market activity?
Caplight tracks bids, offers, and trades in Encellin's shares on secondary markets.